Biogen looks to solidify leading position in MS
Biogen Idec has given an upbeat R&D presentation and outlined a pipeline which consists of more than 60 programmes in 15 indications, six of which are in late-stage trials.
Read MoreAuthor: Kevin Grogan
Pfizer and Ligand celebrate European approval of Fablyn
Pfizer has got the thumbs-up from regulators in Europe for the investigational osteoporosis compound Fablyn.
Read MoreNovartis/Antisoma’s NSCLC Phase III trial extended to Japan
Novartis is extending late-stage trials of an investigational lung cancer drug licensed from the UK’s Antisoma to Japan.
Read MoreNovartis hopes to capture 90% stake in its Indian unit
Novartis has launched an offer to increase its stake in the Swiss major’s Indian subsidiary in a deal that is valued at around 4.4 billion Indian rupees, or $87 million.
Read MoreGSK puts 800 patents in ‘pool’, expands trials transparency
Having recently proposed a new approach to tackling health problems specific to the developing world, GlaxoSmithKline has announced plans to put 800 of its patents into a pool to stimulate research into neglected tropical diseases.
Read More- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
